Phase shift colloids as ultrasound contrast agents
AssigneeSonus Pharmaceuticals, Inc.
InventorSteven C. Quay
Life of this patent
Estimating the term…
Loading patent…
AssigneeSonus Pharmaceuticals, Inc.
InventorSteven C. Quay
Estimating the term…
Agents for enhancing the contrast in a diagnostic ultrasound procedure comprise colloidal dispersions of the liquid-in-liquid type, i.e., emulsions or microemulsions, in which the dispersed liquid phase is a high vapor pressure chemical which undergoes a phase change from a dispersed liquid to a highly echogenic dispersed gaseous foam or kugelschaum following administration to an organism. The liquid state of the dispersed phase allows one to manufacture extremely stable, pharmaceutically acceptable emulsions with particle sizes typically below 1000 nm. The gaseous state at body temperature yields highly echogenic microbubbles, typically below 10,000 nm in diameter, which are effective as ultrasound contrast agents. Intravenous, intraarterial, oral, intraperitoneal, and intrauterine dosage forms, methods of administration, and imaging techniques are described.
A sterile colloidal dispersion for providing ultrasound contrast in a subject comprising, as the dispersed phase, dodecafluoropentane, said dodecafluoropentane being present in an amount in said dispersion such that, upon administration to said subject of said dodecafluoropentane, dodecafluoropentane gas will be present in an amount diagnostically effective for ultrasound contrast, an aqueous continuous phase, and at least one amphiphilic fluorine-containing surfactant.
Dependencies are inferred from the claim text.